Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 10, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 250,000 ordinary shares of 25 pence each.
- Purchase Price: 1,456.18 pence per share.
- Treasury Shares Held: 199,341,678 shares following the transaction.
- Shares in Issue: 5,787,161,745 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares and the increase in Treasury stock resulting from the repurchase of 250,000 shares on October 10, 2006. This action was executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase (250,000 shares at 1,456.18 pence) against the company's cash position in broader financial reports.
- Confirm the updated share count (5,787,161,745 in issue) for earnings per share calculations.
- Review the remaining authorization for share buybacks from the May 17, 2006 Annual General Meeting to assess future capital return potential.